Sydney-based health information company Genome.One has secured a new partnership for its health information technology with Sanford Health, one of the biggest health systems in the US.
The deal, backed by the Garvan Institute of Medical Research, sees Genome.One’s self-phenotyping platform linking patient-provided data with the most up-to-date research and genetic knowledge.
Marcel Dinger, CEO of Genome.One, said that the partnership would enable integration of comprehensive patient information to unlock the benefits of advances in genetic knowledge for patients, such as diagnosis of rare diseases and uncovering treatments for previously untreatable conditions.
Dr Dinger said that the Sanford Health partnership was an “exciting first step in the use of intelligent clinical data capture in primary care” and Sanford’s adoption of Genome.One’s health information technology is “paving the way towards other global partnerships and continued relations between the two health companies”.
{loadposition peter}“Australia’s Genome.One strives to lead the integration of genomic information into health care. We hope that Sanford Health’s investment in Australian technology will be part of a broader partnership as we work together to develop innovative systems for healthcare in both countries.”
Dr Cornelius Boerkoel of Sanford Health said that the partnership with Genome.One forms a crucial piece of its Imagenetics program.
“The self-phenotyping program will allow us to further integrate patient-generated and clinical data with genetic information. The integration of data from many sources will help Sanford’s primary care physicians provide the best care to our patients and will be critical in realising the benefits of genome-based personalised health care,” Dr Boerkoel said.
Dr Boerkoel said the platform will go live across Sanford Health - with 45 hospitals and nearly 300 clinics - as part of the company’s drive to accelerate its growing genomic health care capabilities in the coming months.